Niemann-Pick disease (NPD) is a rare, inherited lysosomal storage disorder characterised by the harmful accumulation of lipids in various organs, primarily the liver, spleen, lungs, and brain. The disease is named after Albert Niemann and Ludwig Pick, who first described it in the early 20th century. The pathogenesis of Niemann-Pick disease is intricately linked to disruptions in lipid metabolism within the cell, leading to the accumulation of lipids such as sphingolipids, which are essential components of cell membranes. This accumulation causes multisystem, often fatal, disease.¹ 

Overview of niemann-pick disease

The Niemann-Pick disease is an autosomal recessive disorder classified into three main types: Type A, Type B, and Type C, each with distinct genetic and clinical features.²

Type A and Type B are caused by mutations in the SMPD1 gene, which encodes the enzyme acid sphingomyelinase (ASM). This enzyme is crucial for the breakdown of sphingomyelin, a type of sphingolipid that is highly concentrated in the fatty sheath that insulates neurons in the brain, called myelin. Mutation of the SMPD1 gene causes decreased activity of the enzyme. Type A NPD typically presents in infancy and is characterised by severe neurodegeneration and premature death. In contrast, Type B NPD has a later onset and predominantly affects visceral organs such as the lungs, so affected individuals often survive into adulthood.

Type C NPD is caused by mutations in the NPC1 or NPC2 genes, which encode proteins NCP1 and NCP2. These are involved in the intracellular trafficking of cholesterol and other lipids. The mutation causes the proteins not to function, leading to a buildup of cholesterol in lysosomes, which are responsible for the breakdown of material in the cell. This type of disease often presents in childhood or adolescence and is marked by progressive neurodegeneration, hepatosplenomegaly (enlargement of the liver and spleen) and pulmonary complications.

Lipid metabolism and accumulation in niemann-pick disease

Lipids are vital compounds involved in numerous cellular processes, including membrane structure, energy storage, and signalling. The metabolism of lipids involves their synthesis, modification, and breakdown. These processes are tightly regulated to maintain cellular homeostasis. Disruption in any of these processes can lead to lipid accumulation.¹

In type A and B NPD, the accumulation of sphingolipids is due to the deficient activity of the acid sphingomyelinase enzyme, which is involved in their breakdown in the cell. In type C NPD, mutations to proteins involved in transporting lipids known as cholesterol lead to impaired trafficking out of the cell and accumulation in the cell. This accumulation disrupts normal cellular function and leads to the progressive damage of affected organs.

Type A and B: acid sphingomyelinase deficiency

In type A and B Niemann-Pick disease, mutations in the SMPD1 gene result in deficient activity of acid sphingomyelinase(ASM). The enzyme ASM is responsible for the hydrolysis (breakdown) of sphingomyelin to ceramide and phosphorylcholine. When ASM activity is reduced or absent, sphingomyelin accumulates within lysosomes, forming lipid-laden macrophages, also known as foam cells.¹

The accumulation of sphingomyelin disrupts cellular membranes and impairs the function of lysosomes, which are critical for degrading and recycling cellular components. This lysosomal dysfunction triggers a cascade of pathological events, including inflammation, oxidative stress, and cell death, which contribute to the clinical manifestations of the disease. In Type A, the accumulation in neurons leads to severe neurodegeneration. In contrast, in Type B, the accumulation in visceral organs such as the liver, spleen, and lungs results in organomegaly (organ enlargement) and dysfunction.⁴

Type C: Impaired intracellular lipid trafficking

Type C Niemann-Pick disease is caused by mutations in the NPC1 or NPC2 genes, which encode proteins involved in the transport of cholesterol and other lipids within cells. NPC1 is a membrane protein located in the late endosomes and lysosomes, while NPC2 is a soluble protein that binds cholesterol within the lysosome. These proteins work together to facilitate the movement of cholesterol out of lysosomes.

Mutations in NPC1 or NPC2 disrupt this transport process, leading to the accumulation of unesterified cholesterol (free cholesterol) and other lipids within lysosomes. This accumulation interferes with the normal trafficking and distribution of lipids, causing secondary storage of sphingolipids, glycosphingolipids, and other lipids. The resultant lipid storage leads to lysosomal dysfunction, altered cellular signalling, and impaired autophagy, contributing to cellular damage and neurodegeneration.²

Symptoms and diagnosis

Symptoms of Niemann-Pick disease vary widely depending on the type and severity of the disease. Diagnosis of Niemann-Pick disease typically involves a combination of clinical evaluation, biochemical testing, and genetic analysis ⁴

Type A 

Typically presents in infancy with symptoms such as hepatosplenomegaly, failure to thrive, motor development and growth delay and severe neurodegeneration. Infants with type A often experience rapid neurological decline, leading to fatality before the age of four years old. ³

Type B 

Has a more variable presentation, with some individuals remaining asymptomatic into adulthood. Common symptoms include hepatosplenomegaly (liver and spleen enlargement), pulmonary difficulties including recurrent lung infections and more rarely, neurological complications. 3

Enzyme assays can be used to measure the activity and concentration of the ASM enzyme, which can diagnose types A and B. This involves a blood test. Additional genetic testing may be required.

Type C

Presents with a wide range of neurological symptoms, including ataxia, vertical supranuclear gaze palsy, dystonia, and cognitive decline. Hepatosplenomegaly and pulmonary involvement are also common. The age of onset can vary from infancy to adulthood, with a corresponding range of disease severity. ⁴

For Type C, the Filipin test is used to detect intracellular cholesterol accumulation, alongside genetic testing for mutations in NPC1 and NPC2. This involves a skin biopsy. 

Treatment approaches

Currently, there is no cure for Niemann-Pick disease, but various therapeutic strategies aim to manage symptoms and slow disease progression. These include:

• Enzyme Replacement Therapy (ERT): For type A and B Niemann-Pick disease, ERT with recombinant human acid sphingomyelinase (rhASM) has shown promise in reducing sphingomyelin accumulation and improving organ function⁵
• Substrate Reduction Therapy (SRT): This approach involves reducing the synthesis of sphingolipids to decrease their accumulation. Miglustat, an inhibitor of glycosphingolipid synthesis, is used for treating Type C Niemann-Pick disease and has shown benefits in stabilising neurological symptoms⁶
• Hematopoietic Stem Cell Transplantation (HSCT): HSCT has been explored as a potential treatment for Niemann-Pick disease, particularly for Type B. This procedure aims to replace the defective enzyme with functional enzyme-producing cells
• Gene Therapy: Advances in gene therapy hold promise for Niemann-Pick disease. Techniques such as adeno-associated virus (AAV) vectors are being investigated to deliver functional copies of the SMPD1, NPC1, or NPC2 genes to affected cells
• Supportive care: symptomatic treatment, including physical therapy, occupational therapy, and nutritional support, is crucial for managing the complications of Niemann-Pick disease and improving the quality of life for affected individuals

Research and future directions

Ongoing research into the molecular mechanisms of Niemann-Pick disease and lipid metabolism is critical for developing effective therapies. Areas of interest include:

• Understanding pathophysiology: Investigating how lipid accumulation leads to cellular dysfunction and neurodegeneration can provide insights into potential therapeutic targets
• Biomarkers for early diagnosis: Identifying biomarkers for early and accurate diagnosis of Niemann-Pick disease can facilitate timely intervention and improve outcomes
• Novel therapeutic approaches: exploring new treatments, such as small molecule drugs, gene editing technologies, and combination therapies, can expand the options for managing Niemann-Pick disease

Conclusion

Niemann-Pick disease (NPD) is a rare, autosomal recessive lysosomal storage disorder characterised by the abnormal accumulation of lipids, leading to multisystem disease. It highlights the profound impact of lipid metabolism on human health. In NPD, enzymatic deficiencies or impaired trafficking in the cell leads to the accumulation of a type of lipids called sphingolipids, causing disease. Understanding the intricate relationship between lipid metabolism and Niemann-Pick disease pathogenesis is essential for developing effective treatments and improving the lives of those affected by this challenging condition. Ongoing research and advances in therapeutic strategies offer hope for better management and, ultimately, a cure for Niemann-Pick disease.